Joshua Bauml1, Jiyoung Kim2, Xiaochen Zhang3, Charu Aggarwal2, Roger B Cohen2, Kathryn Schmitz3. 1. Perelman Center for Advanced Medicine, Perelman School of Medicine at the University of Pennsylvania, South Pavilion, Floor 10, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. joshua.bauml@uphs.upenn.edu. 2. Perelman Center for Advanced Medicine, Perelman School of Medicine at the University of Pennsylvania, South Pavilion, Floor 10, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. 3. Penn State College of Medicine, Hershey, PA, USA.
Abstract
PURPOSE: Patients with human papillomavirus (HPV)-related head and neck cancer (HNC) have a better prognosis relative to other types of HNC, making survivorship an emerging and critical issue. Exercise is a core component of survivorship care, but little is known about how many survivors of HPV-related HNC can safely be advised to start exercising on their own, as opposed to needing further evaluation or supervised exercise. METHODS: We utilized guidelines to identify health issues that would indicate value of further evaluation prior to being safely prescribed unsupervised exercise. We performed a retrospective chart review of 150 patients with HPV-related HNC to assess health issues 6 months after completing definitive therapy. Patients with at least one health issue were deemed appropriate to receive further evaluation prior to prescription for unsupervised exercise. We utilized logistic regression to identify clinical and demographic factors associated with the need for further evaluation, likely performed by outpatient rehabilitation clinicians. RESULTS: In this cohort of patients, 39.3% could safely be prescribed unsupervised exercise 6 months after completing definitive therapy. On multivariable regression, older age, BMI >30, and receipt of radiation were associated with an increased likelihood for requiring further evaluation or supervised exercise. CONCLUSIONS: Over half of patients with HPV-related HNC would benefit from referral to physical therapy or an exercise professional for further evaluation to determine the most appropriate level of exercise supervision, based upon current guidelines. IMPLICATIONS FOR CANCER SURVIVORS: Development of such referral systems will be essential to enhance survivorship outcomes for patients who have completed treatment.
PURPOSE:Patients with human papillomavirus (HPV)-related head and neck cancer (HNC) have a better prognosis relative to other types of HNC, making survivorship an emerging and critical issue. Exercise is a core component of survivorship care, but little is known about how many survivors of HPV-related HNC can safely be advised to start exercising on their own, as opposed to needing further evaluation or supervised exercise. METHODS: We utilized guidelines to identify health issues that would indicate value of further evaluation prior to being safely prescribed unsupervised exercise. We performed a retrospective chart review of 150 patients with HPV-related HNC to assess health issues 6 months after completing definitive therapy. Patients with at least one health issue were deemed appropriate to receive further evaluation prior to prescription for unsupervised exercise. We utilized logistic regression to identify clinical and demographic factors associated with the need for further evaluation, likely performed by outpatient rehabilitation clinicians. RESULTS: In this cohort of patients, 39.3% could safely be prescribed unsupervised exercise 6 months after completing definitive therapy. On multivariable regression, older age, BMI >30, and receipt of radiation were associated with an increased likelihood for requiring further evaluation or supervised exercise. CONCLUSIONS: Over half of patients with HPV-related HNC would benefit from referral to physical therapy or an exercise professional for further evaluation to determine the most appropriate level of exercise supervision, based upon current guidelines. IMPLICATIONS FOR CANCER SURVIVORS: Development of such referral systems will be essential to enhance survivorship outcomes for patients who have completed treatment.
Entities:
Keywords:
Exercise; HPV; Head and neck cancer; Human papillomavirus; Survivorship
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Christine H Chung; Qiang Zhang; Christina S Kong; Jonathan Harris; Elana J Fertig; Paul M Harari; Dian Wang; Kevin P Redmond; George Shenouda; Andy Trotti; David Raben; Maura L Gillison; Richard C Jordan; Quynh-Thu Le Journal: J Clin Oncol Date: 2014-09-29 Impact factor: 44.544
Authors: Corinne R Leach; Kathryn E Weaver; Noreen M Aziz; Catherine M Alfano; Keith M Bellizzi; Erin E Kent; Laura P Forsythe; Julia H Rowland Journal: J Cancer Surviv Date: 2014-10-16 Impact factor: 4.442
Authors: Sara S Cheng; Jeffrey E Terrell; Carol R Bradford; David L Ronis; Karen E Fowler; Mark E Prince; Theodoros N Teknos; Gregory T Wolf; Sonia A Duffy Journal: Arch Otolaryngol Head Neck Surg Date: 2006-06
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Lauren C Capozzi; Kathryn C Nishimura; Margaret L McNeely; Harold Lau; S Nicole Culos-Reed Journal: Br J Sports Med Date: 2015-05-12 Impact factor: 13.800
Authors: Thomas A Wadden; Sheri Volger; David B Sarwer; Marion L Vetter; Adam G Tsai; Robert I Berkowitz; Shiriki Kumanyika; Kathryn H Schmitz; Lisa K Diewald; Ronald Barg; Jesse Chittams; Reneé H Moore Journal: N Engl J Med Date: 2011-11-14 Impact factor: 91.245
Authors: Susan A Sabatino; Ralph J Coates; Robert J Uhler; Lori A Pollack; Linda G Alley; Laura J Zauderer Journal: J Clin Oncol Date: 2007-05-20 Impact factor: 44.544
Authors: Wendy Demark-Wahnefried; Kathryn H Schmitz; Catherine M Alfano; Jennifer R Bail; Pamela J Goodwin; Cynthia A Thomson; Don W Bradley; Kerry S Courneya; Christie A Befort; Crystal S Denlinger; Jennifer A Ligibel; William H Dietz; Melinda R Stolley; Melinda L Irwin; Marcas M Bamman; Caroline M Apovian; Bernardine M Pinto; Kathleen Y Wolin; Rachel M Ballard; Andrew J Dannenberg; Elizabeth G Eakin; Matt M Longjohn; Susan D Raffa; Lucile L Adams-Campbell; Joanne S Buzaglo; Sharyl J Nass; Greta M Massetti; Erin P Balogh; Elizabeth S Kraft; Anand K Parekh; Darshak M Sanghavi; G Stephen Morris; Karen Basen-Engquist Journal: CA Cancer J Clin Date: 2017-11-22 Impact factor: 508.702